EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events

Pharmakovigilanzstudie zu GLP-1-Rezeptoragonisten für metabolische und nutritive unerwünschte Ereignisse

Long He, Qiuyu Li, Yongfeng Yang, Jiahao Li, Wei Luo, Yilan Huang, Xiaoyan Zhong

Frontiers in Pharmacology · 08.07.2024 · 15

DOI: 10.3389/fphar.2024.1416985 ↗

Auf einen Blick

Die FAERS-Analyse fand für einige GLP-1-Rezeptoragonisten Signale für metabolische und nutritive unerwünschte Ereignisse. Besonders Exenatid, Liraglutid und Semaglutid waren häufiger betroffen.

Fragestellung

Welche Sicherheitsignale zu metabolischen und nutritiven unerwünschten Ereignissen zeigen verschiedene GLP-1-Rezeptoragonisten in FAERS?

Methode

Auswertung von FAERS-Meldungen vom Markteintritt bis zum 2. Quartal 2023; Signalidentifikation mit ROR, PRR, Empirical Bayesian Geometric Mean und Bayesian Confidence Propagation Neural Network.

Ergebnisse

Gefiltert wurden 10.450 Berichte zu Exenatid, 2.860 zu Liraglutid, 240 zu Albiglutid, 4.847 zu Dulaglutid, 2.905 zu Semaglutid, 1.089 zu Tirzepatid und 13 zu Lixisenatid. Signale: Albiglutid n = 1, Lixisenatid n = 2, Tirzepatid n = 11, Exenatid n = 12, Liraglutid n = 16, Semaglutid n = 20, Dulaglutid n = 22.

Schlussfolgerung der Autor:innen

Die Autor:innen folgern, dass Exenatid, Liraglutid und Semaglutid anfälliger für metabolische und nutritive AEs sind als andere GLP-1-RAs. Für Liraglutid, Dulaglutid, Semaglutid und Tirzepatid wird wegen Dehydration besondere Aufmerksamkeit empfohlen.

Kernaussagen

  • FAERS-Signale für metabolische und nutritive AEs bei mehreren GLP-1-RAs
  • Exenatid, Liraglutid und Semaglutid mit höheren ROR-Werten
  • Dehydration war häufig bei Liraglutid, Dulaglutid, Semaglutid und Tirzepatid

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 08.07.2024. Verfasst von Long He und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, China. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are employed extensively in the management of type 2 diabetes and obesity. However, there is a paucity of real-world data on their safety and tolerability for metabolic and nutritional adverse events in large sample populations. This study aimed to analyse the metabolic and nutritional safety signatures of different GLP-1 RAs by exploring the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).

Methods

AEs data were extracted from the FDA Adverse Event Reporting System database for each GLP-1 RA from the time of its launch until the second quarter of 2023. The reported odds ratio (ROR), proportional reporting ratio (PRR), Empirical Bayesian Geometric Mean and Bayesian Confidence Propagation Neural Network were employed to identify AE signals.

Results

A system organ class of metabolism and nutrition disorders was employed to filter AE reports, resulting in the identification of 10,450 reports for exenatide, 2,860 reports for liraglutide, 240 reports for albiglutide, 4,847 reports for dulaglutide, 2,905 reports for semaglutide, 1,089 reports for tirzepatide, and 13 reports for lixisenatide. Semaglutide (ROR, 3.34; 95%CI, 3.22), liraglutide (ROR, 2.78; 95%CI, 2.69), and exenatide (ROR, 2.15; 95%CI, 2.11) were associated with metabolism and nutrition disorders. The number of AE signals detected were as follows: albiglutide (n = 1), lixisenatide (n = 2), tirzepatide (n = 11), exenatide (n = 12), liraglutide (n = 16), semaglutide (n = 20), dulaglutide (n = 22). Dehydration was the most frequent AE contributing to serious outcomes for liraglutide (n = 318, 23.93%), dulaglutide (n = 434, 20.90%), semaglutide (n = 370, 25.10%) and tirzepatide (n = 70, 32.86%). The time to onset (TTO) of AE was statistically different between exenatide and the other GLP-1 RAs ( p < 0.001), and the Weibull parameters for dehydration for liraglutide, dulaglutide, and semaglutide analyses all showed an early failure-type profile.

Conclusion

Our study suggests that exenatide, liraglutide, and semaglutide are more susceptible to metabolic and nutritional AEs than other GLP-1 RAs. Liraglutide, dulaglutide, semaglutide, and tirzepaptide’s potential to induce dehydration, necessitates special attention. Despite certain deficiencies, GLP-1 RAs have considerable potential for the treatment of eating disorders.

Schlagwörter

Stichwörter der Autor:innen

FAERSGLP-1 receptor agonistsadverse eventsmetabolism and nutrition disorderspharmacovigilance

Autor:innen und Institutionen

  • Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
  • School of Pharmacy, Southwest Medical University, Luzhou, China.

Zitieren

APA

He, L., Li, Q., Yang, Y., Li, J., Luo, W., Huang, Y., & Zhong, X. (2024). Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1416985

Vancouver

He L, Li Q, Yang Y, Li J, Luo W, Huang Y, et al. Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1416985

BibTeX
@article{He2024,
  author = {He, Long and Li, Qiuyu and Yang, Yongfeng and Li, Jiahao and Luo, Wei and Huang, Yilan and Zhong, Xiaoyan},
  title = {Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1416985}
}
Kostenlos starten →